Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

 

Reality Check on Kidney Cancer

Market access for kidney cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 62% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In December 2019, the FDA approved Teva Pharmaceuticals USA, Inc.'s and Endo International plc unit Par Pharmaceuticals' everolimus for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; advanced renal cell carcinoma; renal angiomyolipoma and tuberous sclerosis complex; progressive neuroendocrine tumors of pancreatic origin; and progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable
  • Key Findings: Coverage is strong for all products in the class, with prior authorization required by most payers to ensure standard of care is followed and products are used according to their FDA-approved label and/or follow national guidelines in cancer treatment

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.

MMIT-RC_Thumbnail_1-1.png